Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20767611 | 0.85 | NPC1 (0.32) | NPC1DGAT1 | |
| SCHEMBL29896746 | 0.85 | NPC1 (0.32) | NPC1DGAT1 | |
| SCHEMBL23229294 | 0.75 | DGAT1 (0.34) | NPC1DGAT1 | |
| SCHEMBL19203911 | 0.75 | DGAT1 (0.41) | NPC1KLKB1DGAT1 | |
| SCHEMBL20401183 | 0.73 | NPC1 (0.39) | NPC1DGAT1 | |
| SCHEMBL20699444 | 0.72 | KMT2A (0.41) | NPC1KLKB1DGAT1 | |
| SCHEMBL19204028 | 0.70 | DGAT1 (0.34) | NPC1KLKB1DGAT1 | |
| SCHEMBL2376935 | 0.69 | DGAT1 (0.36) | NPC1KLKB1DGAT1 | |
| SCHEMBL21751708 | 0.69 | DGAT1 (0.38) | NPC1KLKB1DGAT1 | |
| SCHEMBL20767635 | 0.69 | NPC1 (0.35) | NPC1KLKB1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2022-11-24 | — | — | US | disclosed |
| US-20210315904-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210171523-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC (US) | 2021-06-10 | — | — | US | disclosed |
| US-20200071329-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2020-03-05 | — | — | US | disclosed |
| US-10377755-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190040062-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2019-02-07 | — | — | US | disclosed |
| WO-2017132474-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2017-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377755-B2 | BCL-2 inhibitors | BCL2L1, BCL2, BCL2A1 | NPC1 2259/4885KLKB1 4534/4885DGAT1 2751/4885 |
| US-20200071329-A1 | BCL-2 INHIBITORS | BCL2L1, BCL2, BCL2A1 | NPC1 2259/4885KLKB1 4534/4885DGAT1 2751/4885 |
| US-20210315904-A1 | BCL-2 INHIBITORS | BCL2L10, BCL2, BCL2L11 | NPC1 3788/4885KLKB1 3570/4885DGAT1 4227/4885 |
| US-20210171523-A1 | BCL-2 INHIBITORS | BCL2L1, BCL2, BCL2A1 | NPC1 2259/4885KLKB1 4534/4885DGAT1 2751/4885 |
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | BCL2L11, BCL2L10, BCL2 | NPC1 3924/4885KLKB1 2992/4885DGAT1 4510/4885 |
| US-20190040062-A1 | BCL-2 INHIBITORS | BCL2L1, BCL2, BCL2A1 | NPC1 2259/4885KLKB1 4534/4885DGAT1 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.